Placeholder Banner

Statement Regarding Interactions With Healthcare Professionals

February 19, 2009

Statement regarding Interactions with Healthcare Professionals

BIO and our member companies remain dedicated to the improvement of patient care and the advancement of medical science.  In pursuing this mission, we recognize that adherence to strict ethical standards and compliance with applicable laws is critical to our industry’s ability to continue our collaboration with healthcare professionals and maintain the trust of our patients.  For these reasons, BIO supports the principles in PhRMA’s Code governing interactions with healthcare professionals, and will continue to encourage its members to maintain the highest standards for ethical business practices and socially responsible industry conduct related to company interactions with healthcare professionals.

Specifically, BIO encourages each of its member companies that are involved in the marketing of biologics or other pharmaceuticals to United States healthcare professionals to adopt a transparent and rigorous code of conduct, such as the PhRMA Code, tailored as appropriate to its own particular circumstances and which also ensures compliance with all applicable local, state, and federal laws and regulations.  BIO members that wish to sign on to the PhRMA Code may do so, even if they are not PhRMA members.

 

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…